These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29341351)

  • 1. Discordant von Willebrand factor (VWF) activity in patients with VWF p.Gly1324Ser confirmed in vitro.
    Bowman M; Rimmer E; Houston DS; Israels SJ; James P
    Haemophilia; 2018 Mar; 24(2):e57-e59. PubMed ID: 29341351
    [No Abstract]   [Full Text] [Related]  

  • 2. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor.
    Eikenboom JC; Castaman G; Kamphuisen PW; Rosendaal FR; Bertina RM
    Thromb Haemost; 2002 Feb; 87(2):252-7. PubMed ID: 11859851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of cysteine 584 impairs the storage and release, but not the synthesis of von Willebrand factor.
    Daidone V; Barbon G; Pontara E; Cattini GM; Gallinaro L; Zampese E; Pizzo P; Casonato A
    Thromb Haemost; 2014 Dec; 112(6):1159-66. PubMed ID: 25230768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations.
    Rastegar-Lari G; Ajzenberg N; Ribba AS; Vereycken-Holler V; Legendre P; Villoutreix B; Meyer D; Baruch D
    Thromb Haemost; 2001 Dec; 86(6):1459-65. PubMed ID: 11776314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a new type 2M von Willebrand disease mutation also at position 1324 of von Willebrand factor.
    Hilbert L; Fressinaud E; Ribba AS; Meyer D; Mazurier C;
    Thromb Haemost; 2002 Apr; 87(4):635-40. PubMed ID: 12008946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease.
    Cumming A; Grundy P; Keeney S; Lester W; Enayat S; Guilliatt A; Bowen D; Pasi J; Keeling D; Hill F; Bolton-Maggs PH; Hay C; Collins P;
    Thromb Haemost; 2006 Nov; 96(5):630-41. PubMed ID: 17080221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.
    Rauch A; Caron C; Vincent F; Jeanpierre E; Ternisien C; Boisseau P; Zawadzki C; Fressinaud E; Borel-Derlon A; Hermoire S; Paris C; Lavenu-Bombled C; Veyradier A; Ung A; Vincentelli A; van Belle E; Lenting PJ; Goudemand J; Susen S
    Thromb Haemost; 2016 May; 115(5):950-9. PubMed ID: 26791163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Willebrand's disease caused by compound heterozygosity for a substitution mutation (T1156M) in the D3 domain of the von Willebrand factor and a stop mutation (Q2470X).
    Lethagen S; Isaksson C; Schaedel C; Holmberg L
    Thromb Haemost; 2002 Sep; 88(3):421-6. PubMed ID: 12353070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease.
    Tjernberg P; Castaman G; Vos HL; Bertina RM; Eikenboom JC
    Br J Haematol; 2006 May; 133(4):409-18. PubMed ID: 16643449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phenotype and genotype analysis of three Chinese pedigrees with von Willebrand disease].
    Qin HH; Wang XF; Ding QL; Xu GQ; Zhang LW; Dai J; Lu YL; Xi XD; Wang HL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):99-102. PubMed ID: 21429375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism and classification of von Willebrand disease.
    Sadler JE; Matsushita T; Dong Z; Tuley EA; Westfield LA
    Thromb Haemost; 1995 Jul; 74(1):161-6. PubMed ID: 8578450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
    Graf L; Moffat KA; Carlino SA; Chan AK; Iorio A; Giulivi A; Hayward CP
    Int J Lab Hematol; 2014 Jun; 36(3):341-51. PubMed ID: 24750681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Willebrand disease, type 2B: A diagnosis more elusive than previously thought.
    Favaloro EJ
    Thromb Haemost; 2008 Mar; 99(3):630-1; author reply 632-3. PubMed ID: 18327414
    [No Abstract]   [Full Text] [Related]  

  • 16. A common splice site mutation is shared by two families with different type 2N von Willebrand disease mutations.
    Nesbitt IM; Hampton KK; Preston FE; Peake IR; Goodeve AC
    Thromb Haemost; 1999 Sep; 82(3):1061-4. PubMed ID: 10494764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genetic defect of type I von Willebrand disease "Vicenza" is linked to the von Willebrand factor gene.
    Randi AM; Sacchi E; Castaman GC; Rodeghiero F; Mannucci PM
    Thromb Haemost; 1993 Feb; 69(2):173-6. PubMed ID: 8456430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Willebrand disease masquerading as haemophilia A.
    Mazurier C
    Thromb Haemost; 1992 Apr; 67(4):391-6. PubMed ID: 1631785
    [No Abstract]   [Full Text] [Related]  

  • 19. Type 1 von Willebrand disease: application of emerging data to clinical practice.
    Collins PW; Cumming AM; Goodeve AC; Lillicrap D
    Haemophilia; 2008 Jul; 14(4):685-96. PubMed ID: 18510569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined partial exon skipping and cryptic splice site activation as a new molecular mechanism for recessive type 1 von Willebrand disease.
    Gallinaro L; Sartorello F; Pontara E; Cattini MG; Bertomoro A; Bartoloni L; Pagnan A; Casonato A
    Thromb Haemost; 2006 Dec; 96(6):711-6. PubMed ID: 17139363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.